{"entity":{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","aka":["Endostar","rh-endostatin"],"tldr":"Endostar is Simcere's recombinant endostatin, approved in China in 2005 with chemotherapy for advanced non-small-cell lung cancer, one of the first angiogenesis inhibitors approved anywhere.","summary":"Recombinant human endostatin (Endostar) was developed in China and is marketed by Simcere in Nanjing. The NMPA (then the SFDA) approved it in September 2005 in combination with vinorelbine and cisplatin for advanced non-small-cell lung cancer, a year after bevacizumab's US approval. It remains widely used in China and is being tested with immunotherapy.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Endostar","url":"https://clinicaltrials.gov/search?intr=Endostar"}],"tags":["china","nmpa-approved"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["simcere"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00576914","nct01124253","nct02579564"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo China deep dive","editedOn":"2026-09-16"},"modality":"Recombinant angiogenesis inhibitor protein","mechanism":"A recombinant form of endostatin, a fragment of collagen XVIII that stops the growth of new blood vessels a tumour needs.","approvals":[{"region":"CN","year":2005,"indication":"Advanced non-small-cell lung cancer, with vinorelbine and cisplatin"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/recombinant-human-endostatin/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/"}],"trial":[{"id":"nct00576914","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer","route":"/trials/nct00576914/"},{"id":"nct01124253","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct01124253/"},{"id":"nct02579564","kind":"trial","name":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","route":"/trials/nct02579564/"}]}}